drugset / Trial / NCT00985647

Pharmacokinetics of Lamivudine at Two Different Doses

NCT00985647

Phase 1/2 Completed 24 enrolled Kirby Institute
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of the study is to measure the pharmacokinetics (how a drug is absorbed, distributed and eliminated from the body) of lamivudine (3TC) and its active component after 3TC is given at two different doses, 300mg and 150mg once daily.

Timeline

Start
2009-12
Primary completion
2010-02
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lamivudine Other / unclassified 150 mg Oral
Comparator Lamivudine Other / unclassified 300 mg Oral